Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.68 |
| ▸ | CA1 | P00915 | 5/20 | 0.68 |
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | CA7 | P43166 | 5/20 | 0.68 |
| ▸ | CA9 | Q16790 | 5/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650418 | 0.88 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL762861 | 0.88 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL90400 | 0.87 | CA1 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16951249 | 0.83 | PRKCA (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2161045 | 0.83 | SLC7A5 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2668277 | 0.82 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL46504 | 0.82 | CA12 (0.91) | CA12CA1CA2CA7CA9 | |
| Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 | 0.82 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13898816 | 0.81 | SLC7A5 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL475791 | 0.81 | SLC7A5 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124767-B2 | Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-8124767-B2 | Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-8124767-B2 | Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | disclosed |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| WO-2007058504-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES, LTD. (KR) | 2007-05-24 | — | — | WO | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | CA12 1330/4885CA1 1776/4885CA2 401/4885 |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | BTD, HLCS, BPGM | CA12 2975/4885CA1 3691/4885CA2 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.